MYCOPLASMOSIS - A SERIOUS PROBLEM OF POULTRY INDUSTRY

Similar documents
Suggestions to prevent / control Respiratory Disease Complex in poultry

MG and MS Control in Layers

Poultry Disease Manual Characteristics And

Avian Influenza. Regional Workshops: Veterinary Discussion. Will Garton

CLASSIFICATION OF AVIAN MYCOPLASMAS

INCLUSION BODY HEPATITIS AND HYDROPERICARDIUM SYNDROME (ADENOVIRUS INFECTIONS)

RESPIRATORY DISEASES. Photo: Monique de Vrijer. Text: Monique de Vrijer Photos: Pauline van Schaik

INFECTIOUS CORYZA. Slide study set #10. Random Sample. Prepared by: National Animal Disease Center. P.O. Box 70. Ames, Iowa and R. B.

Control of mycoplasma infection of poultry by antibiotics

Differential Diagnosis of Respiratory Disease in Broilers

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

Etiology. Paramyxovirus type 1 = Newcastle disease.

Overview. Organism Economic Impact Epidemiology Transmission Clinical Signs Diagnosis and Treatment Prevention and Control Actions to take

Monitoring for Mycoplasma

INFLUENZA-2 Avian Influenza

CAUSATIVE AGENT. Bacterium Hemophilus paragallinarum.

Home News Chickens Turkeys Processing Other Poultry Regions Even

INFO SHEET. E. coli Versus. Environmental Management: Which Has Evolved Faster?

16 th JPC REM ESA M ohammedia 18-19th April Surveillance of low pathogenic Avian Influenza virus

This paper is in two Sections (A and B) and instructions relating to the number of questions to be answered are given at the head of each Section.

Fraser Menzies Veterinary Epidemiology Unit DARD

FALSE LAYERS UPDATE EGG & PULLET FARMERS WORKSHOP 2017 DAN VELDMAN

MS-H Vaccine Eyedrop Suspension

WELCOME TO POULTRY TECHNICAL MEET

Frequently Asked Questions on Avian Influenza

FREQUENTLY ASKED QUESTIONS 1 Avian Influenza in Birds

2. Avian influenza and the viruses that cause it

SCIENTIFIC DISCUSSION

Newcastle disease. in the Czech Republic

PUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA

Self-declaration of the recovery of freedom from highly pathogenic avian influenza in poultry by the Netherlands

Self-declaration of Belgium regarding the recovery of the HPAI free status in poultry

Field experience with vaccination in turkeys in Morocco. Taoufik RAWI M.C.I Santé Animale (Morocco)

Mycoplasma driving you crazy?

Immunity and Poultry Health (3)

making LT protection safer and easier

Avian Influenza. Poultry Growers September 2015

VETERINARY SERVICES POLICY STATEMENT

Evolution of influenza

OIE Situation Report for Highly Pathogenic Avian Influenza

OIE Situation Report for Avian Influenza

TRUSTWORTHY POULTRY CEVAC CORYMUNE RANGE. Unique combination vaccines to protect against Coryza and Salmonella. Supported by CEVAC CORYMUNE 4K

WORLD OSTRICH ASSOCIATION UNDERSTANDING AND CONTROLING AVIAN INFLUENZA RISKS IN OSTRICH

Laboratory Diagnosis of Avian Influenza and Newcastle Disease

Salt Intoxication in Commercial Broilers and Breeders a Clinical and Pathological Description

Managing Salmonella Risk. Carl Heeder, DVM

Avian Flu. Tyler Cymet, DO Associate Vice President for Medical Education American Association of Colleges of Osteopathic Medicine

SALMONELLA, MYCOPLASMA, AND AVIAN INFLUENZA MONITORING IN PARENT BREEDER FLOCKS

Influenza. Gwen Clutario, Terry Chhour, Karen Lee

OIE Situation Report for Highly Pathogenic Avian Influenza

E. coli peritonitis. Bernie Beckman, DVM Hy-Line International. Genetic Excellence. Genetic Excellence. Hy-Line International

OIE Situation Report for Highly Pathogenic Avian Influenza

Worldwide perspective on Infectious Bronchitis. Ruth Bouwstra, DVM, PhD Turkey February 2017

Keeping first class eggs flying high.

International Journal of Science, Environment and Technology, Vol. 6, No 1, 2017,

Evaluation of Biosecurity Status in Commercial Broiler Farms in Sri Lanka

Surviving an HPAI Outbreak

Current Situation with Avian Mycoplasmosis Prevention and Control

AVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.

Respiratory disease in backyard poultry

VETERINARY EXTENSION

Recommended Resources: The following resources may be useful in teaching this

Poultry Biosecurity PREPARING FOR FALL AI THREAT

Updations on the epidemiological situation of Avian Influenza (AI) in Libya. The 11 th JPC REMESA Algiers, Algeria 24-25November2015

Highly Pathogenic Avian Influenza:

Unit C: Poultry Management. Lesson 3: Poultry Health Management

State of U.S. Egg Layer Health 2013 Annual Survey

Molecular diagnosis of infectious bronchitis: recent developments. Richard Currie

Introduction. Transmission

VIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks


Gumboro Disease: where are we with IBDV epidemiology. J.J. (Sjaak) de Wit, DVM, PhD, dipl ECPVS GD Deventer, The Netherlands

COLIBACILLOSIS IN LAYERS: AN OVERVIEW

EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL. Unit G5 - Veterinary Programmes

Enhancing animal health security and food safety in organic livestock production

AVIAN INFLUENZA. Frequently Asked Questions and Answers

Influenza: The Threat of a Pandemic

TURKEY CORYZA SYNONYMS: "Alcaligenes Alcaligenes Rhinotracheitis Turkey Bordetellosis

A. No. There are no current reports of avian influenza (bird flu) in birds in the U.S.

True Pathogens of the Enterobacteriaceae: Salmonella, Shigella & Yersinia Salmonella

INFORMATION NOTE ON AVIAN INFLUENZA AND MIGRATORY BIRDS

The importance of temperature control to optimising chick health

Agricultural Outlook Forum Presented: February 16, 2006 THE CURRENT STATE OF SCIENCE ON AVIAN INFLUENZA

Early Diagnosis: A Critical Step in Bird Flu Prevention

THE PENNSYLVANIA/VIRGINIA EXPERIENCE IN ERADICATION OF AVIAN INFLUENZA (H5N 2) Gerald J. Fichtner

RHODOCOCCUS EQUI. Post-mortem Environmental Persistence Specific Control Measures Release of Animals from Isolation

Country and Cackle Hatcheries more conventional breeds Murray McMurray s rare breeds Adult Chickens purchase from a reputable neighbor Adoption: you

Influenza B viruses are not divided into subtypes, but can be further broken down into different strains.

Practical Biosecurity Check List

Mark Wustenberg DVM, John Kirk, DVM, MPVM, Hank Spencer DVM

On Farm Hygiene & Bio-security. Dr. Stephen Graham

by Dr Thijs van Dijk and Anna-Christina Riebau Marketing Poultry Vaccines, Lohmann Animal Health

Principles for event based and active avian influenza surveillance. Les Sims Asia Pacific Veterinary Information Services

Avian Flu Update. Dr. Sheila E. Purdum Extension Poultry Specialist Professor, Animal Science, UNL

Highly Pathogenic Avian Influenza. Outbreak Prevention Protocol September 2015

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination

IMPORT HEALTH STANDARD FOR THE IMPORTATION OF CHICKEN HATCHING EGGS INTO NEW ZEALAND FROM AUSTRALIA

Alberta Poultry Industry Emergency Management Team. Date: April 28, 2015 No. Pages (Including cover page): 5

Mexico H7N3 HPAI Summary

Management of poultry disease in large, commercially farmed flocks

Transcription:

By, Dr. J. L. Vegad Advisor Phoenix Group MYCOPLASMOSIS - A SERIOUS PROBLEM OF POULTRY INDUSTRY Mycoplasmosis, commonly known as chronic respiratory disease of chickens, has existed in our country since time immemorial and was largely controllable. Recently, however, it appears to have emerged with renewed vigour, has become more common and a serious challenge to the industry. Why? But before we examine this vital aspect of Why?, let us have a quick look at what mycoplasmas are? Cause The disease is caused by a mycoplasma known as Mycoplasma gallisepticum (MG).The strains of MG may differ markedly in virulence, that is, in the degree of their disease-producing power. Some strains of MG are mild while others are highly virulent (very harmful). Mycoplasma is similar to bacteria, but lacks a cell wall. Lack of wall makes MG extremely fragile. They are easily killed by disinfectants, heat, and sunlight. They remain alive in the environment, outside the bird, for only up to 3 days. For this reason, MG is fairly easy to eliminate on single-age, all-in all-out poultry farms. Spread M. gallisepticum enters through the respiratory tract and/or eye. It is transmitted through direct contact of infected birds, or through the environment, dust, soil, drinking water, and feed. It spreads only short distances by air (horizontal transmission). Once a chicken is infected, the infection is of long duration. The organism is present in the respiratory tissues in high levels and is shed into the environment and eggs. After several weeks, the level of infection and shedding of the organism decreases. But even then the infection persists in the flock indefinitely and the chickens may shed the organism periodically, especially following a period of stress. This makes elimination of MG extremely difficult in multi-age breeder and laying complexes. The disease is spread from farm to farm mainly by movement of contaminated people, equipment, and vehicles. Thus basic biosecurity is the best means of preventing introduction of MG into layer and breeders complexes. Because once infected, birds remain carriers for life. Egg transmission (vertical transmission) to broiler progeny occurs at a low level from infected breeders. However, horizontal infection then readily occurs in broiler houses. The organism is also spread by wild birds. Wild birds may become infected and shed MG.

The Disease Process After entering the respiratory tract, the organism attaches to the lining epithelial cells. It secretes hydrogen peroxide which causes oxidative stress on the cell membrane. This facilitates its penetration. Penetration of M. gallisepticum into cells occurs within 5 minutes and the number of intracellular mycoplamas (i.e., inside the cells) increases in 24 hours. Spread to other organs, for example, brain, indicates that brief systemic (blood) infections occur. Infection to oviduct may result because of its closeness to infected abdominal air sacs. Although always considered as a pathogen (disease-producing organism) of the mucosal surface of the respiratory tract, MG is able to penetrate cells. Once inside the cells, it easily avoids the action of antibodies and some antibiotics. This, in turn, enables the organism to pass through the respiratory mucosal barrier and cause systemic infection. Thus, the cell invasion plays a major role in the systemic spread of M. gallisepticum and in escaping from the host defences. This, in turn, allows its survival in the bird and persistence of infection, hence the name chronic respiratory disease (CRD). Why is M. gallisepticum a serious challenge to commercial poultry? There are four basic reasons: 1. Our country witnessed the arrival of Avian Influenza in February 2006. Because of the stringent measures taken by the Government of India, the highly pathogenic form of the disease (HPAI) was brought under control but the low pathogenic form of the virus (LPAI) kept circulating, became endemic, and got itself firmly established as a permanent resident. Not only that, but during the six intervening years, it sharpened its razor and increased its disease-producing power (virulence). This happened because of the constant point mutations that occurred in its genes encoding haemagglutinin and/or neuraminidase surface glycoproteins (antigenic drift). Antigenic drift gradually changes the structure of haemagglutinins and neuraminidases resulting in increased disease-producing power. As a result, infections by drift variants of LPAI in the field have become widespread and very harmful. More recently, co-infection of M. gallisepticum and LPAI virus ((H3N8) in chickens has been reported. In the light of this, it is suggested that LPAI may predispose the birds to M. gallisepticum infection and vice versa. That is, infection with M. gallisepticum may predispose the bird to the variant form of LPAI. This may account for the increased occurrence and increased mortality associated with M. gallisepticum nowadays. 2. An important feature of M. gallisepticum is its antigenic variability. To put it simply, it keeps changing its surface proteins (antigens). Proteins constitute more than two-thirds of the mycoplasma membrane, the rest being membrane lipids. The plasma membrane of M. gallisepticum contains approximately 200 2

polypeptides which are associated with surface antigenic variation. These antigens have been identified. They play key roles in the development of the disease (pathogenesis) and immune responses. M. gallisepticum is highly committed to antigenic variation and changes in the expression of the surface proteins. This leads to the production of atypical or variant strains of M. gallisepticum. As a result, the immunity produced by the administered vaccines is unable to deal effectively with the variant form of M. gallisepticum, and the infection may persist despite vaccination. Thus, antigenic variation is one of the simplest strategies adopted by this organism to avoid destruction by the immune defences of the bird. 3. Another characteristic feature of M. gallisepticum its phenotypic switching. To put it simply it is a very complex way in which this organism changes its surface antigens not only while outside the birds but also while inside the bird. These changes allow the organism to avoid the immune response of the bird, and therefore it persists in the bird for a longer period. M. gallisepticum has an inherent mechanism of making rapid and sudden changes in its expression of proteins in response to antibodies. Thus, this organism uses phenotypic switching for its survival in the bird. In other words, M. gallisepticum may persist in the bird even in the presence of systemic or local antibody (carrier state). 4. Yet another important factor in the control of mycoplasmosis is the complex immune mechanisms involved in protecting the bird following vaccination. For example, there is poor correlation between the levels of circulating antibody and protection of the bird. It has been found that antibody in the respiratory secretions play a role in resistance against M. gallisepticum. Respiratory tract antibodies inhibit attachment of the organism to tracheal epithelial cells, which is one important mechanism of protection. It has now been established that although local immunity plays a main role in controlling M. gallisepticum infection, cellmediated immune system is also involved. There is significant involvement of natural killer and cytotoxic-t cell responses. To sum up, M. gallisepticum infection is a serious challenge because antigenic variation and phenotypic switching enable the organism to escape from the immune defences of the bird. This enables it to establish a chronic infection despite a strong immune response. Moreover, M. gallisepticum may hide from bird s defences by entering into the cells. Since antibodies and antibiotics cannot penetrate the cells, this strategy helps in its survival and persistence of the infection. Incubation Period The incubation period varies from 6-21 days. However, development of clinical signs can be highly variable depending on M. gallisepticum strain virulence (disease-producing power), complicating infections, and environmental 3

and other stress factors. Thus, many variable factors influence the onset and extent of clinical disease. Therefore, meaningful incubation periods cannot be stated. Layer birds usually develop clinical infections at the onset of egg production. Clinical Signs The most characteristic signs are tracheal rales (abnormal respiratory sounds), nasal discharge, and coughing. Feed consumption is reduced, and the birds lose weight. In laying flocks, egg production drops. However, flocks may show serological evidence of infection without clinical signs. Male birds may show more prominent signs, and the disease is more severe during winter. In broiler flocks, most outbreaks occur after four weeks of age. Signs are usually more marked than those observed in mature birds. Severe outbreaks with high morbidity (birds affected) and mortality, seen in broilers, are usually due to concurrent infections are usually due to concurrent infections and environmental factors. Morbidity and Mortality Although M. gallisepticum is the main cause of chronic respiratory disease, other organisms usually cause complications. Severe air sac infections, usually called complicated CRD (CCRD) or air sac disease is the condition more commonly observed in the field. Newcastle disease (Ranikhet disease), infectious bronchitis, or even LPAI virus may precipitate outbreaks of M. gallisepticum infection. E. coli is the most common complicating organism. The effects of M. gallisepticum, E. coli, and infectious bronchitis (IB) virus infections alone or together have been reported. As mentioned earlier, recently co-infection of M. gallisepticum and LPAI virus ((H3N8) in chickens has also been reported. Mortality may be negligible in adult laying flocks, but there can be reduction in egg production. In broilers, mortality may vary from low in uncomplicated disease to severe in complicated outbreaks. Poor growth adds to further losses. Postmortem Lesions Lesions may not be visible or consist mainly of inflammatory exudate in nasal and paranasal passages, trachea, bronchi, and air sacs. In severe cases, there is airsacculitis and air sacs usually contain cheese-like material (caseous exudate) resulting in high mortality. These lesions are mainly because of the complication caused by E. coli infection. Oviducts distended with exudates (salpingitis) have been associated with decreased egg production in M. gallisepticum-infected flocks. Immunity 4

Recovered birds have some degree of immunity. However, recovered birds may still carry the organism and can transmit infections to susceptible birds by contact or egg transmission. As already mentioned, there is poor correlation between the levels of circulating antibody and protection. Antibodies in the respiratory secretions play a role in resistance against M. gallisepticum. They inhibit attachment of the organism to tracheal epithelial cells, which is one important mechanism of immune-mediated protection. It has now been established that although local immunity plays a main role in controlling M. gallisepticum infection, there is also significant involvement of natural killer and cytotoxic-t cell responses in mycoplasma infection However, changes in M. gallisepticum surface proteins which result in antigenic variation and phenotypic switching (discussed above), enable the organism to escape from the host immune defences (immune evasion) and establish a chronic infection despite a strong immune response. Moreover, the organism may hide from bird s defences by entering into cells (cell invasion) and spread systemically which help in its survival and persistence of infection. Diagnosis The standard method for M. gallisepticum diagnosis is isolation and identification of the organism. Serological procedures are useful for flock monitoring of M. gallisepticum control programmes. Haemagglutination-inhibition (HI) and ELISA tests have been commonly used to confirm reactors. Polymerase chain reaction (PCR) is used for rapid diagnosis. A positive serological test along with history, clinical signs and postmortem lesions allow a presumptive diagnosis, pending isolation and/or identification of the organism. Low pathogenic form of avian influenza, Newcastle disease, infectious bronchitis, infectious laryngotracheitis, infectious coryza and other respiratory pathogens should be considered in the differential diagnosis. Treatment In the field, many cases of M. gallisepticum infection are complicated by other diseaseproducing bacteria. Therefore, effective treatment must also attack the secondary invaders. Most strains of mycoplasma M. gallisepticum are sensitive to a number of antibiotics, but are resistant to penicillins or other antibiotics which act by inhibiting cell wall biosynthesis. M. gallisepticum may develop resistance to commonly used antibiotics. Antibiotics are usually given in feed or water. A combination of colistin, tylosin, ciprofloxacin, and bromhexidine (a bronchodilator) in drinking water at the dosage of 1ml/2 litres of water for 3-5 days has been found effective. In case of severe 5

infections, amikacin and tylosin combination each as 15 mg/kg body weight can be given as injection. This is very helpful. However, complete elimination of M. gallisepticum from all birds in an infected flock by antibiotic treatment is an unrealistic hope. The treatment should be regarded as a method for short-term control of disease and economic losses, rather than as a long-term solution to the problem. Prevention and Control The continued presence and high incidence of MG in commercial poultry indicates that earlier efforts at its eradication were not very successful. Therefore, a three-prong vigorous attack is required to deal with the problem of mycoplasmosis. It is extremely important that all the three measures are applied simultaneously. This is because each one has its own advantages and limitations, as explained below. However, if applied together, they bear fruit. 1. Use of antibiotics: For example antibiotics such as kitamycin and colistin can be given in the feed regularly as antibiotic growth promoters. They are very helpful in the prevention of CRD. Limitation: The antibiotics will have no effect on the organisms present inside the cells, and therefore complete elimination of M. gallisepticum in an infected flock cannot be achieved. The organisms present inside the cells escape the action of antibiotics; birds become carriers of infection and continue to shed the organisms. This results in contamination of the environment and spread of infection. 2. Use of vaccines: (a) Killed vaccines: M. gallisepticum killed vaccines (bacterins) protect young birds from infection with virulent M. gallisepticum and commercial egg layers from M. gallisepticum-induced drops in egg production. Limitation: Antibodies will have no effect on the organisms present within the cells. However, killed vaccines have been shown to reduce but not eliminate colonization by M. gallisepticum following infection. They are thought to be of low value in long-term control of infection on multiple age production sites. Regarding effect of killed vaccines on the spread of the organism, there is some reduction in shedding, but vaccination does not reduce horizontal spread of M. gallisepticum between laying hens. (b) Live vaccines: These are of three types: F strain vaccine, 6/85 strain vaccine, and ts-11 vaccine. Because of their greater safety (relative avirulence and low potential for transmission to unvaccinated flocks), both 6/85 and ts-11 6

vaccines may be preferred than F strain when M. gallisepticum vaccination is necessary. Limitation: Because they are live vaccines, there are concerns for the safety of F, 6/85, and ts-11 strains. Even though these vaccines are generally very safe, they may have the potential for infecting unvaccinated flocks. Live vaccines should be used very carefully and administered following strictly the manufacturer s instructions and with careful consideration for the safety of unvaccinated flocks. 3. Management: Because M. gallisepticum can be transmitted by egg, maintaining chicken flocks free of M. gallisepticum is possible only by starting with breeding stocks that are free of the infection. Then, they should be reared with adequate biosecurity to avoid introduction of the organism. To sum up, each measure has its limitations. Moreover, because of overcrowding and lapses in biosecurity, maintaining M. gallisepticum-free poultry flocks may be difficult or impossible. It is therefore of utmost importance that all the three measures, namely, administration of antibiotics, proper vaccination, and good management must be exercised together with full force to keep mycoplasmosis under control. Authors s Suggestions and Comments In M. gallisepticum infection, there is poor correlation between the levels of circulating antibody and protection. Therefore, before killed vaccines are given, the birds must be primed with a live vaccine to ensure production of local immunity in the respiratory tract. As already discussed, local immunity gives more protection than systemic immunity of killed vaccines. Killed vaccines do not produce effective local immunity. Repeating killed vaccines twice or thrice may not be helpful. This is particularly important for hatchery. Antibiotics should be changed periodically to avoid development of resistance. Stringent biosecurity is extremely important in the control of disease for two reasons. Firstly, since M. gallisepticum spreads only short distances by air, where excellent biosecurity is practised, there have been many cases when infection has not spread to neighbouring houses within a complex. Secondly, biosecurity would prevent any infection spread by the vaccinated birds. Good management by ensuring good ventilation, no overcrowding, and good nutrition are very helpful. Finally, it is strongly emphasized that M. gallisepticum must be controlled at all cost. If this is not done, apart from inflicting the damage on its own, the disease 7

will also act as a great predisposition to E. coli, Newcastle disease, infectious bronchitis, and possibly also to drift variant of LPAI. To conclude, it is unlikely that MG will be eradicated from the commercial poultry industry in the coming years. However, though biosecurity programmes and effective use of vaccines, losses can be reduced. ----------------------------- 8